Tech Company Inital Public Offerings

Immunome IPO

Based in Exton, Immunome is now a public company.

Transaction Overview

Company Name
Announced On
10/1/2020
Transaction Type
IPO
Amount
$39,000,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows:approximately $6.5 million to fund further development of our IMM-ONC-01 program;approximately $5.8 million to fund further development of our IMM-BCP-01 program;approximately $5.9 million to advance our platform and research pipeline; andthe remainder to fund other research and development activities, working capital and general corporate purposes.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
665 Stockton Dr. 300
Exton, PA 19341
USA
Overview
Immunome (Nasdaq: IMNM) is a biopharmaceutical company with a patented native, human antibody platform which enables us to harness the natural curative power of the human immune system.
Profile
Immunome LinkedIn Company Profile
Social Media
Immunome Company Twitter Account
Company News
Immunome News
Facebook
Immunome on Facebook
YouTube
Immunome on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Purnanand Sarma
  Purnanand Sarma LinkedIn Profile  Purnanand Sarma Twitter Account  Purnanand Sarma News  Purnanand Sarma on Facebook
Chief Scientific Officer
Michael Morin
  Michael Morin LinkedIn Profile  Michael Morin Twitter Account  Michael Morin News  Michael Morin on Facebook
Co-Founder
Scott Dessain
  Scott Dessain LinkedIn Profile  Scott Dessain Twitter Account  Scott Dessain News  Scott Dessain on Facebook
VP - Bus. Development
Karen Lundgren
  Karen Lundgren LinkedIn Profile  Karen Lundgren Twitter Account  Karen Lundgren News  Karen Lundgren on Facebook
VP - Engineering
Pavel Nikitin
  Pavel Nikitin LinkedIn Profile  Pavel Nikitin Twitter Account  Pavel Nikitin News  Pavel Nikitin on Facebook
VP - R & D
Lauren Pitt
  Lauren Pitt LinkedIn Profile  Lauren Pitt Twitter Account  Lauren Pitt News  Lauren Pitt on Facebook
VP - R & D
Matthew Robinson
  Matthew Robinson LinkedIn Profile  Matthew Robinson Twitter Account  Matthew Robinson News  Matthew Robinson on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/1/2020: Bloomscape venture capital transaction
Next: 10/1/2020: Siren venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary